Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19072317 | 1.00 | SCN9A (1.00) | SCN9AFPR2 | |
| SCHEMBL14743902 | 1.00 | SCN9A (1.00) | SCN9AFPR2 | |
| SCHEMBL16158884 | 1.00 | SCN9A (1.00) | SCN9AFPR2 | |
| SCHEMBL14743760 | 1.00 | SCN9A (1.00) | SCN9AFPR2 | |
| SCHEMBL22779559 | 1.00 | SCN9A (1.00) | SCN9AFPR2 | |
| SCHEMBL22779560 | 0.92 | SCN9A (0.85) | SCN9AFPR2 | |
| SCHEMBL18798948 | 0.90 | FPR2 (0.82) | SCN9AFPR2 | |
| SCHEMBL14743210 | 0.89 | SCN9A (0.81) | SCN9AFPR2 | |
| SCHEMBL19072283 | 0.88 | SCN9A (0.78) | SCN9AFPR2 | |
| SCHEMBL19072096 | 0.87 | SCN9A (0.77) | SCN9AFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2753606-B1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2017-07-05 | — | — | EP | claimed |
| US-9163008-B2 | Pyrimidines as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2015-10-20 | — | — | US | claimed |
| US-20140303139-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2014-10-09 | — | — | US | claimed |
| WO-2013030665-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2013-03-07 | — | — | WO | claimed |
| EP-3293184-B1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2020-12-16 | — | — | EP | disclosed |
| EP-3293184-B1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2020-12-16 | — | — | EP | disclosed |
| US-10774050-B2 | Pyrimidines as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774050-B2 | Pyrimidines as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10196364-B2 | Pyrimidine carboxamides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10196364-B2 | Pyrimidine carboxamides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20190002412-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2019-01-03 | — | — | US | disclosed |
| US-20190002412-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2019-01-03 | — | — | US | disclosed |
| US-9163008-B2 | Pyrimidines as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140303139-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2014-10-09 | — | — | US | disclosed |
| US-20140303139-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2014-10-09 | — | — | US | disclosed |
| US-20140303139-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2014-10-09 | — | — | US | disclosed |
| WO-2014135955-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014135955-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2013030665-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013030665-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196364-B2 | Pyrimidine carboxamides as sodium channel blockers | CACNA1A, TRPV1, TRPA1 | SCN9A 85/4885FPR2 906/4885 |
| US-20190002412-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | P2RX3, CACNA1A, P2RX4 | SCN9A 83/4885FPR2 1198/4885 |
| US-10774050-B2 | Pyrimidines as sodium channel blockers | P2RX3, CACNA1A, P2RX4 | SCN9A 83/4885FPR2 1198/4885 |
| US-20140303139-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | P2RX1, P2RX4, P2RX2 | SCN9A 70/4885FPR2 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.